Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.69 USD
-0.36 (-5.11%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $6.67 -0.02 (-0.30%) 4:48 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRCA 6.69 -0.36(-5.11%)
Will VRCA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
Other News for VRCA
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and Verrica Pharmaceuticals (VRCA)
Biotech Alert: Searches spiking for these stocks today